Polymorphic Compound Forms for mTORC1 Modulation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is an urgent need for more effective treatments for diseases associated with mTORC1 dysregulation, which are prevalent in conditions such as diabetes, epilepsy, neurodegeneration, immune response, suppressed skeletal muscle growth, and cancer, as current treatments are inadequate.

Innovation Solution

Development of compounds, such as compound A, which selectively modulate mTORC1 activity by existing in various solid forms (e.g., Forms A, B, and C) that enhance aqueous solubility, stability, and ease of formulation, allowing for effective treatment of mTORC1-related disorders.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If compound A is developed as an mTORC1 modulator, then therapeutic effectiveness is improved, but solubility and stability are insufficient

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidsolubility and stability

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent applies parameter changes by developing multiple polymorphic forms (Forms A, B, and C) of compound A, each with distinct crystal structures and physical properties. These different polymorphic forms exhibit varying degrees of solubility and stability, allowing optimization of therapeutic effectiveness while addressing solubility and stability concerns through selection of appropriate polymorphic forms.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates composite material systems by formulating compound A in different polymorphic forms with specific physical characteristics. Each polymorphic form represents a composite arrangement of molecules in distinct crystalline structures, enabling tailored selection based on required solubility and stability profiles for different therapeutic applications.

Inventive Principle:

Principle #40Composite materials

2Adaptability or versatility

If multiple polymorphic forms are developed, then formulation flexibility is improved, but manufacturing complexity increases

Engineering Contradiction:

Improveformulation flexibilityVSAvoidmanufacturing complexity

Core Design Contradiction:

Adaptability or versatilityVSEase of manufacture

Solution Approach 1:

The patent segments the single compound A into multiple distinct polymorphic forms (Forms A, B, and C), each with unique X-ray diffraction patterns and physical properties. This segmentation allows formulators to select specific polymorphic forms based on desired formulation characteristics, thereby improving formulation flexibility while maintaining clear distinctions between forms for manufacturing control.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent performs preliminary characterization of multiple polymorphic forms during the development phase, establishing their distinct physical properties, stability profiles, and formulation characteristics before clinical implementation. This preliminary action enables selection of the most appropriate polymorphic form for each specific therapeutic indication, reducing later manufacturing complexities.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS12252456B2Polymorphic compounds and uses thereof

Publication Date: 2025.03.18 SUPERNUS PHARMACEUTICALS INC

AI summary

The present invention relates to compounds and methods useful for selectively modulating mTORC1 activity.